ESC 365 - Doctor Christopher Blaum

Speaker illustration

Doctor Christopher Blaum

University Heart and Vascular Centre Hamburg (UHZ), Hamburg (Germany)

Inflammation and cholesterol associated residual cardiovascular risk and its dependence on chronic kidney disease in statin treated patients with coronary artery disease

Event: ESC Congress 2024

Topic: Epidemiology, Prognosis, Outcome

Session: Lipid-lowering treatment: impact on the atherosclerotic plaque and outcomes

Evaluating risk-based allocation strategies for PCSK9 inhibitors: results from a simulation study in a contemporary ASCVD cohort

Event: ESC Congress 2023

Topic: Drug therapy

Session: Risk factors and prevention: lipids (2)

Inflammatory risk: predictions

Event: ESC Preventive Cardiology 2023

Topic: Biomarkers

Session: Inflammation-driven cardiovascular risk

Target populations and treatment cost for bempedoic acid and PCSK9 inhibitors: a simulation study in a contemporary CAD cohort

Event: ESC Congress 2021 - The Digital Experience

Topic: Lipid-Lowering Agents

Session: Highlights from the Young on cutting edge therapy for lowering lipids

Risk scores for risk stratification in chronic coronary syndrome and their improvement by Gensini and SYNTAX scores

Event: ESC Congress 2021 - The Digital Experience

Topic: Epidemiology, Prognosis, Outcome

Session: Coronary Artery Disease (Chronic)/Chronic Coronary Syndromes ePosters

The impact of the revised ESC Dyslipidaemia Guidelines on lipid-lowering therapy: simulating the need for PCSK9 inhibition in a contemporary ASCVD cohort

Event: ESC Congress 2020

Topic: Drug therapy

Session: Risk Factors and Prevention ePosters

The impact of modifiable life style risk factors on inflammation in patients with coronary artery disease: modelling a target population for anti-inflammatory treatment

Event: ESC Congress 2019

Topic: Lifestyle Modification

Session: CAD - Lifestyle modification and non-pharmacological treatment

ESC 365 is supported by

novartis

Explore sponsored resources